Scancell Holdings - SCIB2 also shown to synergise with checkpoint inhibitor blockade
SCLP Tue, 24 Mar 2015, 02:20pm GMT
Scancell Holdings plc is pleased to announce new data demonstrating that animals treated with a combination of SCIB2, Scancell's ImmunoBody® vaccine in development for the treatment of lung, oesophageal, prostate and other epithelial cancers, and checkpoint inhibition, showed enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.
Dr Richard Goodfellow
Joint Chief Executive Officer
Dr Richard Goodfellow, Joint Chief Executive Officer
Fri, 31 Jul 2015, 8:45am BST
Dr Richard Goodfellow, Joint Chief Executive Officer
Tue, 2 Jun 2015, 7:10am BST
Dr Richard Goodfellow, Joint Chief Executive Officer
Tue, 24 Mar 2015, 2:20pm GMT
Mike Mitchell, Director, Equity Research, Director
Thu, 11 Dec 2014, 3:00pm GMT
Dr Richard Goodfellow, Joint Chief Executive Officer
Wed, 10 Dec 2014, 9:00am GMT
Dr Richard Goodfellow, Joint Chief Executive Officer
Wed, 13 Aug 2014, 10:00pm BST
Dr Richard Goodfellow, Joint Chief Executive Officer
Sun, 8 Jun 2014, 10:40pm BST
